Pfizer announced that the U.S. District Court for the District of Delaware upheld its basic patent and the L-malate salt patent covering SUTENT® capsules. This decision, which is subject to appeal, affirms Pfizer’s right to exclusively provide sunitinib malate as SUTENT to patients through the term of the patent, which expires in 2021.
Dietary supplements containing potentially dangerous prescription drug ingredients may still be...
A Spanish court has upheld an appeal by a German pharmaceutical company, ditching a previous...
The lawsuit was filed as a result of Actavis submitting an Abbreviated New Drug Application to...
The Supreme Court seems divided as it considers a high-stakes patent dispute between rival pharmaceutical companies over the world's best-selling multiple sclerosis treatment.
A former senior finance analyst at Merck & Co. is facing an insider trading charge after authorities said Tuesday that he passed secrets to a friend he met at college that earned $722,000 in illegal profits.
Sucampo Pharmaceuticals has announced that it signed an amendment to the existing collaboration and license agreement covering the United States and Canada for AMITIZA with Takeda Pharmaceutical Company.
Under the terms of the settlement, Sucampo and RTU will grant Par a non-exclusive license to market Par's generic version of lubiprostone 8 mcg soft gelatin capsule and 24 mcg soft gelatin capsule in the U.S. for the indications approved for AMITIZA beginning January 1, 2021, or earlier under certain circumstances.
A pharmaceuticals millionaire charged with killing her developmentally disabled son in a deluxe hotel room told jurors Wednesday that she didn't force drugs down his throat, as prosecutors maintain. Taking the stand in her murder trial to give an account she's long yearned to tell, Gigi Jordan depicted a failed murder-suicide.
Public safety advocates are asking the federal government to strengthen warnings on Pfizer's anti-smoking drug Chantix, even as the drugmaker prepares to argue that a bolded warning about psychiatric problems should be removed from its medicine's label.
The scandal and its repercussions will be felt deep into Big Pharma’s operations in emerging markets, causing a fundamental shift in product marketing approaches involving physicians.
A judge has finalized a $190 million settlement between Johns Hopkins Hospital and more than 8,000 patients of a gynecologist who used tiny cameras to secretly photograph women and girls during examinations.
A Baltimore judge was set to hear objections Friday to a preliminary $190 million dollar settlement between Johns Hopkins Hospital System and more than 8,000 patients of a gynecologist who used tiny cameras to secretly photograph women and girls during examinations.
A former executive of drugmaker GlaxoSmithKline and four Chinese co-defendants have been sentenced to prison in a bribery case but may never have to serve that time. China's official Xinhua News Agency said Briton Mark Reilly and his Chinese co-defendants were given a three-year reprieve at their sentencing Friday.
A Detroit-area cancer doctor accused of putting people through unnecessary treatments and then billing insurers for millions of dollars pleaded guilty to fraud Tuesday, admitting that he knew his patients often didn't need chemotherapy.
Some of the nation's largest cities are ratcheting up their criticism of prescription painkillers, blaming the industry for a wave of addiction and overdoses that have ravaged their communities and busted local budgets.
New York's attorney general filed a federal lawsuit Monday seeking to stop a manufacturer from discontinuing its drug widely used to treat Alzheimer's patients, arguing the company is illegally driving patients to its newer patented drug to avoid losses from cheaper generic alternatives coming out next year.
The Food and Drug Administration is considering whether to ban devices used by the Judge Rotenberg Educational Center in Canton, Massachusetts, the only place in the country known to use skin shocks as aversive conditioning for aggressive patients.
The powerful chemical industry is putting its lobbying muscle behind legislation that would establish standards for chemicals used in products from household goods to cellphones and plastic water bottles — but also make it tougher for states to enact their own regulations.
The Department of Justice filed a court motion against the German conglomerate over its advertisements for Phillips' Colon Health, which claims to prevent diarrhea, constipation, gas and bloating. Federal officials say the company does not have reliable scientific evidence to support those claims.
A pharmacist who worked for a Massachusetts company blamed for a nationwide meningitis outbreak that killed 64 people pleaded not guilty to a mail fraud charge as his lawyer said he is concerned he could be made a scapegoat.
A multimillionaire mom killed her autistic 8-year-old son by forcing a toxic cocktail of painkillers and other drugs down his throat with a syringe in a luxury Manhattan hotel room, a prosecutor said as her murder trial opened Wednesday.
A new batch of lawsuits challenge the White House’s mandate that requires employers to provide contraception for employees.
An FBI official in Detroit confirmed that the bureau is looking at an Oregon research center, and investigators have raided facilities in Michigan and Arizona. Besides confirming the existence of an investigation, authorities have been tight-lipped about what they are examining and why.
A former portfolio manager convicted of helping his firm earn more than a quarter-billion dollars illegally through insider trading on a promising Alzheimer's drug trial was sentenced Monday to nine years in prison by a judge who said lengthy incarceration was earned with a staggering fraud that was the biggest of its kind.
The FTC says AbbVie and its partner and Besins Healthcare filed baseless patent infringement lawsuits against Teva Pharmaceutical Industries Ltd. and Perrigo Co. to delay the approval and sale of less-expensive generic versions of the drug.
Hyperion Therapeutics Terminates Diabetes Program - Discovers Serious Misconduct by Andromeda BiotechSeptember 8, 2014 8:35 am | News | Comments
Hyperion Therapeutics today announced it is terminating development of DiaPep277 for newly diagnosed Type 1 diabetes. The company has uncovered evidence that certain employees of Andromeda Biotech, which Hyperion acquired in June 2014, engaged in serious misconduct, including collusion with a third-party biostatistics firm.
Nuvo Research Inc. today announced that it has reached a full settlement with Mallinckrodt Inc. of Nuvo's claims and Mallinckrodt's counterclaim relating to Nuvo's license to Mallinckrodt of the right to market and sell Pennsaid and Pennsaid 2% in the United States.
Various unapproved and improperly labeled drug products that were marketed, sold and distributed via the Internet by Flawless Beauty LLC, of Asbury Park, New Jersey, have been seized by U.S. Marshals at the request of the U.S. Food and Drug Administration and the U.S. Attorney for the District of New Jersey.
- Page 1